KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Deferred Revenue: 2009-2023

Historic Current Deferred Revenue for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2023 value amounting to $2.9 million.

  • Halozyme Therapeutics' Current Deferred Revenue fell 54.51% to $2.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.9 million, marking a year-over-year decrease of 54.51%. This contributed to the annual value of $5.5 million for FY2022, which is 28.60% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Current Deferred Revenue of $2.9 million as of Q3 2023, which was down 5.81% from $3.1 million recorded in Q2 2023.
  • Over the past 5 years, Halozyme Therapeutics' Current Deferred Revenue peaked at $6.9 million during Q2 2022, and registered a low of $1.4 million during Q2 2020.
  • Over the past 3 years, Halozyme Therapeutics' median Current Deferred Revenue value was $5.3 million (recorded in 2021), while the average stood at $4.9 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Current Deferred Revenue slumped by 78.67% in 2020 and then soared by 279.63% in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Current Deferred Revenue (Quarterly) stood at $5.3 million in 2019, then tumbled by 66.80% to $1.7 million in 2020, then surged by 144.90% to $4.3 million in 2021, then increased by 28.60% to $5.5 million in 2022, then slumped by 54.51% to $2.9 million in 2023.
  • Its last three reported values are $2.9 million in Q3 2023, $3.1 million for Q2 2023, and $5.5 million during Q1 2023.